Table 3.
ORs of type 2 diabetes and dyslipidaemia according to quartiles of trans-18:2 fatty acids
| trans-18:2 | Q1 | Q2 | Q3 | Q4 | p for trend |
|---|---|---|---|---|---|
| Median | 0.106 | 0.138 | 0.167 | 0.225 | |
| Type 2 diabetesa | 112 | 105 | 101 | 107 | |
| Model 1 | 1 | 0.83 (0.62, 1.12) | 0.73 (0.54, 0.98) | 0.78 (0.58, 1.06) | 0.12 |
| Model 2 | 1 | 0.78 (0.58, 1.05) | 0.66 (0.49, 0.90) | 0.71 (0.52, 0.98) | 0.05 |
| Model 3 | 1 | 0.81 (0.60, 1.10) | 0.71 (0.52, 0.96) | 0.76 (0.55, 1.04) | 0.12 |
| Hypertriacylglycer olaemiaa,b,c | 104 | 135 | 180 | 201 | |
| Model 1 | 1 | 1.25 (0.94, 1.66) | 1.72 (1.31, 2.27) | 1.88 (1.43, 2.48) | <0.0001 |
| Model 2 | 1 | 1.15 (0.86, 1.55) | 1.67 (1.26, 2.22) | 1.91 (1.43, 2.54) | <0.0001 |
| Model 3 | 1 | 1.27 (0.94, 1.71) | 1.98 (1.48, 2.65) | 2.34 (1.73, 3.17) | <0.0001 |
| High total cholesterola,b,c | 143 | 177 | 216 | 213 | |
| Model 1 | 1 | 1.18 (0.91, 1.53) | 1.38 (1.07, 1.78) | 1.34 (1.03, 1.73) | 0.03 |
| Model 2 | 1 | 1.15 (0.88, 1.50) | 1.34 (1.04, 1.74) | 1.32 (1.02, 1.72) | 0.04 |
| Model 3 | 1 | 1.15 (0.89, 1.51) | 1.36 (1.04, 1.76) | 1.29 (0.98, 1.70) | 0.05 |
| High LDL-cholesterola,b,c | 231 | 277 | 323 | 334 | |
| Model 1 | 1 | 1.16 (0.92, 1.46) | 1.33 (1.06, 1.67) | 1.38 (1.09, 1.74) | 0.007 |
| Model 2 | 1 | 1.12 (0.88, 1.41) | 1.27 (1.01, 1.61) | 1.33 (1.05, 1.68) | 0.02 |
| Model 3 | 1 | 1.13 (0.89, 1.43) | 1.29 (1.02, 1.64) | 1.31 (1.02, 1.68) | 0.03 |
| Low HDL-cholesterola,b | 280 | 280 | 290 | 289 | |
| Model 1 | 1 | 1.00 (0.80, 1.25) | 0.99 (0.79, 1.24) | 1.01 (0.80, 1.27) | 0.95 |
| Model 2 | 1 | 0.94 (0.74, 1.19) | 0.93 (0.73, 1.17) | 0.97 (0.76, 1.24) | 0.86 |
| Model 3 | 1 | 0.98 (0.78, 1.25) | 1.00 (0.78, 1.28) | 1.12 (0.86, 1.44) | 0.34 |
Model 1: adjusted for age, sex and north/south and urban/rural location
Model 2: further adjusted for family history of chronic diseases, education, smoking, alcohol consumption, physical activity and BMI
Model 3: further adjusted for saturated fatty acids and trans-18:1 fatty acids in erythrocytes
Numbers of participants in Q1–Q4 were 694, 694, 693 and 694, respectively. Numbers of cases in each quartile are shown
Participants (n=332) who took fish oil supplements or hypolipidaemic drugs were excluded
Defined by the National Centers for Environmental Prediction/Adult Treatment Panel III criteria for borderline high (1.7 mmol/l for triacylglycerol, 5.17 mmol/l for total cholesterol and 3.4 mmol/l for LDL-cholesterol)